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International Health Law
MAUREEN BEZUHLY, DAVID

P.

FIDLER, ALLYN

L.

TAYLOR, AND MARK

E.

WOJCIK*

In 1997, control of disease continued as a central focus of activity in international public
health law. The World Health Organization (WHO) pursued revision of the International
Health regulations for adoption by the World Health Assembly (WHA) in May 1999. Linkage
between disease and international trade was raised in both judicial and administrative fora. The
WHO worked to build support for development of a framework convention on tobacco,
following its 1996 international regulatory strategy for global tobacco control. The threat of
biological weapons use resulted in the Fall 1997 decision to vaccinate all American military
forces against anthrax, and heightened public health concerns continued into 1998, as tensions
mounted for possible military action in Iraq. Climate change, such as global warming, is increasingly linked in the literature to the emergence, frequency, and range of infectious disease. The
international AIDS pandemic progressed in 1997 despite medical advances in treatment, largely
unavailable to AIDS patients in many countries unable to finance such treatments.
Competition in 1997 culminated in the January 1998 WHO Executive Board selection of
former Norwegian Prime Minister, Dr. Gro Harlem Brundtland, as the next WHO DirectorGeneral, upon WHA approval in May 1998. Dr. Brundtland announced her intentions to
urge public health as a top political priority in WHO member countries, to strengthen recognition
of public health as essential in economic development, and to link WHO actions with those
of the International Monetary Fund and the World Bank.

1. Emerging and Reemerging Infectious Diseases
A.

WORLD HEALTH ORGANIZATION: GENERAL

1. WHO Funding
The financial constraints hindering the WHO's pursuit of its mandate to improve global health
have long been known and lamented. The WHA noted in May 1997 that problems with unpaid

*Maureen Bezuhly (judicial decisions), David P. Fidler (emerging and re-emerging infectious diseases), Allyn
L. Taylor (tobacco control), and Mark E. Wojcik (AIDS) are the authors of this report. Lane Porter facilitated
the report. Maureen Bezuhly is an attorney with the firm Fischbein 0 Badillo * Wagner 9 Harding in New York
City; David Fidler is an associate professor at Indiana University Law School in Bloomington; Allyn Taylor is
an international health law consultant with the World Health Organization and the World Bank; Mark E. Wojcik
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assessed contributions from Members States were growing. The WHA stated that "total unpaid
contributions in respect of 1996 and prior years exceeded US$ 169 million."' Although the WHA
invoked article 7 of the WHO Constitution to suspend voting privileges of Member States in
arrears in their contributions, this penalty seems not to have much effect. The WHA expressed
its "concern at the increasingly large number of Members that have been in arrears in the payment
of their contributions in recent years to an extent which would justify invoking Artide 7 of the
Constitution and the unprecedented level of contributions owed by them." 2
2. Expanded Legal Powersfor WHO?

The reluctance of the WHO to use its international legal powers under the WHO Constitution
is a well-known and increasingly questioned practice of the WHO. A special group empowered
by the WHO Executive Board to review the WHO Constitution issued its report in November
1997,' which includes recommendations to increase the WHO's regulatory powers under article
21 of the WHO Constitution. The special group proposed adding to the WHA's authority
to adopt regulations in article 2 1 the power to adopt regulations: (1)on "standards with respect
to transplantation of tissues and genetic engineering, including cloning" 4 and (2) "concerning
any other health-related matter falling within the functions of the Organization as set forth in
Article 2."'
The proposal on allowing the WHA to adopt standards on transplantation and genetic engineering expands the WHA's regulatory authority into controversial new areas such as xenotransplantation and cloning. The second proposal essentially broadens the WHA's authority to
adopt regulations equaling the authority it has under article 19 to adopt conventions on any matter
within the competence of the WHO. If these proposals are adopted by WHO Member States,
they will represent a significant increase in WHA regulatory powers. Such an increase does not
necessarily imply the WHO altered its preference for non-binding recommendations and guidelines over binding regulations or conventions. In fact, the Director-General restated the traditional
WHO position in May 1997: WHO recommendations and guidelines established through consultative meetings of experts "have proved more effective and more flexible than legally binding
instruments such as conventions, which require lengthy procedures before they come into force." 6
B.

EMERGING AND REEMERGING INFECTIOUS DISEASES (ExCLUDING

HIV/AIDS)

The WHO dedicated World Health Day 1997 to the global problem of emerging and
reemerging infectious diseases (EIDs),7 which demonstrates the continuing prominence of this
is an assistant professor at the John Marshall Law School in Chicago; and Lane Porter practices international
health law in Washington, D.C., and is chair of the International Health Law Committee, liaison to the ABA
Standing Committee on Substance Abuse, and liaison to the ABA AIDS Coordinating Committee.
I. Status of Collection of Assessed Contributions,World Health Assembly Res. WHASO.7 (May 12, 1997).
2. Members in Arrears in the Payment of Their Contributions to an Extent Which Would Justify Invoking Ankle
7 of tbe Constitution, World Health Assembly Res. WHAS0.8 (May 12,1997).
3. Review of the Constitutionand Regional Arrangements of the World Healtb Organization: Report of the Special
Group, World Health Organization EBI01/7 (Nov. 14, 1997).
4. Id.at 6.
5. Id.
6. Cloning, Biomedical Technology, and WHO's Role in Standard-Setting Report by the Director-General,at
8, World Health Organization (May 8, 1997).
7. World Health Day 1997: Emerging Infectious Diseases-GlobalAlert, Global Response (visited Dec. 11,1997)
< http://www.who.ch/whday/l997/EmerglD.html >. The WHO defines emerging and reemerging infectious
diseases as "emerging infectious diseases," which are "diseases of infectious origin whose incidence in humans
has increased within the past two decades or threatens to increase in the near future." WoLD HEALTH ORG.,
WORLD HEALTH REPORT 1996: FIGHTING DISEASE, FOSTERING DEVELOPMENT 1 (1996).
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problem in global public health policy. In 1996 infectious diseases caused 17,312,000 deaths
worldwide, representing 33 percent of all 1996 deaths.8 Infectious diseases remained important
in many diplomatic contexts in 1997, including the attention given to controlling EIDs at the
June 1997 summit of the Group of Seven industrialized countries 9 and at the November
1997 Asia Pacific Economic Cooperation summit.' The United States continued its bilateral
diplomacy on EIDs through the U.S.-Japan Common Agenda, U.S.-European Trans-Atlantic
Agenda, the U.S.-Russian Joint Commission on Economic and Technical Cooperation," and
the U.S.-South Africa Binational Commission." The United States also signed a new, five-year
cooperation agreement with India on EIDs. " In addition, Congress allocated an additional $50
million for fiscal year 1998 to the U.S. Agency for International Development specifically to
help control infectious diseases in foreign countries.' 4 Finally, as 1997 came to a close, infectious
diseases captured worldwide media attention in the form of the transmission to humans of an
avian influenza virus in Hong Kong.' 5
These sections briefly highlight some 1997 developments relating to infectious diseases,
demonstrating that they increasingly pose challenges in many areas of international law.' 6
1. Revision of the InternationalHealtb Regulations
The WHO's revision of the International Health Regulations (IHR) continued during 1997,
with the WHO publishing two progress reports on the IHR revision. 7 In its last progress
report, the WHO stated that the revised IHR would contain important changes "involving a
new approach to mandatory notification as well as a major alteration in the structure of the
IHR.' '8 Instead of requiring notification of only three diseases as at present, the revised IHR

8. WORLD HEALTH ORG., WORLD HEALTH REPORT

1997: CONQUERING SUFFERING, ENRICHING HUMANITY

20 (1997) [hereinafter WORLD HEALTH REPORT19971.
9. SeeStrobe Talbott, Globalization and Diplomacy: A Practitioner'sPerspective, FOREIGN POL'Y, Sept. 22,
1997, at 68 (noting that the spread of infectious diseases received attention at the 1997 G7 summit).
10. Highlights of the APEC Ministers' Statement Issued, BBC Summary of World Broadcasts, Nov. 24, 1997,
available in LEXIS, Nexis Library, Curnws File (notingAPEC ministers' recognition of"the challenge to sustainable
growth posed by emerging infectious diseases and ... the need for further collaboration").
11. OFFICE OF THE VICE PRESIDENT OF THE U.S., STATEMENT ON REPORT OF THE HEALTH COMMITTEE OF THE
U.S.-RussIAN JOINT COMMISSION ON ECONOMIC AND TECHNICAL COOPERATION (Sept. 23, 1997) (visited Dec. 22,
1997) <http://www/usia.gov/regional/bnc/usrussia/gcc9/health.htm>.
12. OFFICE OF THE VICE PRESIDENT OF THE U.S., U.S. SOUTH AFRICA BINATIONAL COMMISSION: SCIENCE AND
TECHNOLOGY COMMrrTEE, PRESS
RELEASE
(July 30, 1997) (visited Dec. 22, 1997) < http://www.usia.gov/regional/

bnc/usafrica/4stp.htm >.
13. US., India Agree to Strengthen Joint Efforts Against Emerging, Re-Emerging Infectious Diseases, COMLINE
DAILY NEWS BIOTECH. & MED. TECH., Dec. 11,1997, available in LEXIS, Nexis Library, Cumws File [hereinafter
U.S,, India].
14. David Brown, U.S. Agency Devotes $50 Million More to Figbt Infectious Diseases Overseas, WASH. POST,
Dec. 18, 1997, at A15.
IS. See Edward A. Gargan, Chicken-Borne Flu Virus Puts Hang Kong on Alert, N.Y. TIMES, Dec. 17, 1997,
at A6; U.S., India, supra note 13; Brown, supra note 14, at A15; Isolation of Avian Influenza A(H5NI) Viruses
from Humam-Hong Kong, 1997-1998, 46 MORBIDITY & MORTALITY WKLY. REP.1205 (1998).
16. For an overview of how emerging infectious diseases intersect with different areas of international law,
see David P. Fidler, The Role ofInternationalLaw in the ControlofEmerging Infectious Diseases, 9 5 BULL. DE L'INsrrrT
PASTEUR57

(1997).

17. Revision of the InternationalHealth Regulations: ProgressReport, December 1996, 72 WKLY. EPIDEMIOLOGICAL
REc. 9 (1997) [hereinafter ProgressReport, December 19961; Revision of the InternationalHealth Regulations: Progress
Report, July 1997, 72 Wkly. Epidemiological Rec. 213 (1997) [hereinafter Progress Report, July 19971. See also
WORLD HEALTH REPORT1997, supa note 8, at 106 (noting on-going IHR revision).
18. Progress Report, July 1997, supra note 17, at 213.
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will "require reporting of a number of defined disease syndromes that are of international
importance.""9 The structural changes planned for the revised IHR involve moving to a framework document containing core provisions and a series of technical annexes detailing specific
obligations.2° Field-testing of syndrome reporting was scheduled to begin in October 1997.2
The WHO anticipates submitting the revised IHR to the WHA in 1999.22
2. InternationalTrade

The WHO and national governments registered much concern in 1997 about the spread
of food borne pathogens through international trade. Leading international and national public
health agencies, including the WHO and the U.S. Centers for Disease Control and Prevention,
sponsored a major conference on emerging food borne pathogens in March 1997, the proceedings of which were published in the influential journal Emerging Infectious Diseases.2

The link between food borne pathogens and growing volumes of international trade in food
and food products implicates international trade law. This link was clearly noticed in early
October 1997 when the Clinton Administration launched a new policy initiative to improve
the safety of food imported into the United States. 4 This policy initiative was provoked by
a New York Times article reporting serious problems with U.S. efforts to monitor food imports. 2
The United States and the European Union (E.U.) are in the midst of a controversy concerning
a plan to ban approximately $4.5 billion in U.S. cosmetics and pharmaceuticals because they
contain bovine-derived tallow and gelatin that could act as vectors of bovine spongiform encephalopathy, which can cause a new variant of the fatal human brain disease called Creuztfeldt-Jakob
disease. 6 In December 1997 the United States blocked the importation of Guatemalan raspberries from March 15, 1998, until August 15, 1998, because of the link between prior imports
and outbreaks of disease in the United States caused by the parasite cyclospora."
Although not a case involving infectious diseases, the WTO panel and Appellate Body"5
decisions in the Beef Hormones Case have implications for sanitary and phytosanitary measures
of WTO Member States that address human, animal, and plant infectious diseases because
these decisions are the first to interpret the WNTO Agreement on the Application of Sanitary
and Phytosanitary Measures (SPS Agreement).5 In April 1996 the United States requested
19. Id.
20. Id. at 214.
21. Id.
22. Progress Report, December 1996, supra note 17, at 10. For scholarly analysis of the IHR revision published
in 1997, see Allyn L. Taylor, Controlling tbe Global Spread of Infictious Diseases: Toward a Reinforced Role for the
InternationalHealtb Regulations, 33 Hous. L. Rv. 1327 (1997); David P. Fidler, Return of the Fourtb Horseman:
Emerging Infectious Diseases and InternationalLaw, 81 MINN. L. Rav. 771 (1997).
23. See Papers from the National Conference on Emerging Food-Borne Pathogens: Implications and Control,

in 3 EMERGING

INFECTIOUS
DISEASES
415

(1997).

24. See James Bennet, President Wants FD.A. to Regulate Foreign Produce, N.Y. TIMES, Oct. 3, 1997, at Al.
Details about the Clinton Administration policy are expected early in 1998. Id.
25. See Jeff Gerth & Tim Weiner, Imports Swamp US. Food-Safety Efforts, N.Y. TIMES, Sept. 29, 1997, at
Al.
26. Barry James, A Tram-Atlantic Beef EU Threatens US. Meat Ban over Inspections, INr'L HERALD TRIB.,
Dec. 19, 1997, at 1.
27. Cyclosporiasis: Guatemalan Raspberries Banned-US (electronic mail communication from ProMED-mail),
Dec. 20, 1997.
28. EC Measures Concerning Meat and Meat Products (Hormones), WTO Doc. No. 5 WT/DS26/AB/R, ST/
DS48/AB/R UJan.16, 1998) [hereinafter Hormones Appellate Report].
29. Agreement on the Application of Sanitary and Phytosanitary Measures, Dec. 15, 1993, MTN/FA IIAIA-4 (1994).
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the establishment of a WTO panel to rule on the compatibility with the GATT and the SPS
Agreement of the European Community (EC) ban on imports of meat raised with growthpromotion hormones.35 The WTO panel found that the EC ban violated articles 3.1, 3.3, 5.1,
and 5.5 of the SPS Agreement." The core panel holding was that the European Community
did not provide a scientific basis or evidence for its import ban. 2 While the Appellate Body
upheld the panel's conclusion that the European Community did not satisfy the science-based
disciplines of the SPS Agreement, and thus was in violation of articles 3.3 and 5.1, it reversed
the panel's rulings that the European Community also violated of articles 3.1 and 5.5 of the
SPS Agreement."
The Appellate Body also reversed the panel's allocation of the burden of proof by holding
that the SPS Agreement requires the complaining member state to make a prima facie case
that the SPS Agreement was violated before the burden shifts to the accused member state. 4
The Appellate Body's allocation of the burden of proof may make it harder for a member
state to challenge the SPS measures of other member states than it would be under the Hormones
Panel Report. 3 In addition, the Appellate Body's interpretations of articles 3 and 5 emphasized
member states' sovereignty in implementing SPS measures;36 such interpretations might make
it easier for a member state to provide scientific justifications for its SPS measures than are
possible under the Hormones Panel Report. 3

At its May 1997 meeting the WHA addressed a number of other issues involving the
intersection of international trade and health: (1) the quality of pharmaceutical products moving
in international commerce;33 and (2) the quality of biological products moving in international
commerce. 9 The WHA also addressed the issue of the cross-border advertising, promotion,
and sale of medical products on the Internet and requested the Director-General to convene

a WHO ad hoc working group to review the concerns arising in this area., °

30. The US-EC dispute over beef hormones extends back nearly ten years. See, e.g., Allen Dick, Note, The
EC Hormones Ban Dispute and the Application of the Dispute Settlement Provisions of the Standards Code, 10 MICH.
J. INT'L L. 872 (1989).
31. Hormones Appellate Report, supra note 28, 1 9.1.
32. For a critical analysis of the Beef Hormones Case, see Steve Charnovitz, Tbe World Trade Organization,
Meat Hormones, and Food Safety, 14 INT'L TRADE REP. 1781 (1997).
33. Hormones Appellate Report, supra note 28, 1 253.
34. Id. 253(a).
35. WTO Beef Hormones: US and EU Both Claim Victory, BRIDoES WKLY. TRADE NEws DIG., Jan. 19, 1998
(noting that the shift in the burden of proof to the complaining party might make SPS challenges more difficult).
36. Hormones Appellate Report, supra note 28, 1 104, 172 (interpreting the relationship between Articles
3.1 and 3.3) and 11 186-87 (interpreting article 5.1's risk assessment mandate not to require any demonstration
of a threshold of risk and to include examination and evaluation of risks not susceptible to investigation by scientific
.methods).
37. For a more detailed analysis of the Hormones Panel Report and the Hormones Appellate Report, see
David P. Fidler, Trade and Health: The Global Spread of Diseases and InternationalTrade, 40 GERMAN Y.B. INT'L
L. (forthcoming 1997).
38. Guidelines on the WHO CertificationScheme on the Quality ofPharmaceuticalProducts Moving in International
Commerce, World Health Assembly Res. WHA50.3 (May 12, 1997).
39. Quality of BiologicalProductsMoving in InternationalCommerce, World Health Assembly Res. WHA50.20
(May 12, 1997). Part of this Resolution requested the Director-General to review the relation between WHO
guidelines on the quality of biological products and WTO agreements, particularly the Agreement on Technical

Barriers to Trade, the SPS Agreement, and the Agreement on Trade-Related Aspects of Intellectual Property
Rights, and to submit a report to the Executive Board in May 1998.
40. Cross-BorderAdvertising, Promotion and Sale of Medical Products Using the Internet, World Health Assembly
Res. WHA50.4 (May 12, 1997).
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3. Biological Weapons
The threat of biological weapons was a theme in literature on EIDs. 41 The stand-offs between
the United Nations and Iraq over inspections of Iraq's nuclear, chemical, and biological weapons
facilities in 1997 highlighted a year in which concern for the proliferation of biological weapons
was high. In August 1997 the prestigious Journalof the American Medical Association devoted
most of an issue to the threat of biological weapons.42 In Geneva, negotiations continued on
drafting a Protocol to the 1972 Biological Weapons Convention43 that would establish a
compliance regime to strengthen the Convention's prohibition on the development, production,
and stockpiling of biological weapons. Many important issues remain unresolved in the negotiations on the Protocol, including the scope and intrusiveness of the compliance regime and
the protection of national security information and private sector confidential information."
Meanwhile, American concerns about countries using biological weapons factored into: (1)
President Clinton's new guidelines for American policy on using nuclear weapons, under which
such weapons may be used against an enemy attacking with biological weapons;4 and (2) the
U.S. military's decision to vaccinate all American forces against anthrax.46
4. InternationalEnvironmental Law
Global warming was in the spotlight in 1997 as states met in Berlin and then in Kyoto to

negotiate a Protocol to the 1992 Climate Change Convention. Global warming was featured
in literature on EIDs because of the prospects that climate change could increase the frequency
and geographical range of certain infectious diseases and their insect vectors. 4' While the argument that global warming will increase infectious disease problems is controversial,48 the very
existence of the controversy makes international
environmental law and its development at
49
Kyoto relevant to global public health policy.

41. See, e.g., Laurie Garrett, The Return of Infectious Diseases, FOREIGN AFF., Jan.-Feb. 1996, at 66.
42. See generally 278 JAMA (1997).
43. Convention on the Prohibition of the Development, Production, and StockpilingofBacteriological [biological] and Toxin Weapons and on Their Destruction, Apr. 10, 1972, 26 U.S.T. 583, 11 1.L.M. 309.
44. See Robert P. Kadlec et al., Biological Weapons Control. Prospectsand Implicationsfor the Future, 278 JAMA
351, 355 (1997).
45. Steven Lee Myers, U.S. "Updates" All-Out Atom War Guidelines, N.Y. TIMES, Dec. 7, 1997, at A3. Such
a position on the use of nuclear weapons raises the question of the policy's compatibility with the International
Court of Justice's interpretation of international law on the use of nuclear weapons contained in its advisory
opinion on the Legality of the Use or Threat of Nuclear Weapons. For more on U.S. concerns about biological
weapons, seeU.S. DEP'T OFDEFENSE,
PROLIFERATION: THREAT AND RESPONSE
(Nov. 25, 1997) (visited Dec. 12,
1997). <http://www.defenselink.mi/pubs/prolif97/index.html>.
46. Steven Lee Myers, US. Armed Forces To Be Vacinated Against Anthrax, N.Y. TIMES, Dec. 16, 1997,
at Al.
47. See, e.g., Richard A. Kerr, Greenhouse Report Foresees Growing Global Stress, 270 SCIENCE 731, 731 (1995)
(describing warnings from UN-sponsored Intergovernmental Panel on Climate Change about the potential spread
of tropical diseases because of global warming). For a fuller discussion of this issue, see CLIMATE CHANGE AND
HUMAN HEALTH 71-105 (A. J. McMichael et al. eds., 1996). See also WORLm HEALTH ORG., HEALTH AND
ENVIRONMENT IN SUSTAINABLE DEVELOPMENT: FIVE YEARS AFTER THE EARTH SUMMIT 124 (1997) (discussing the
impact of climate change on the spread of infectious diseases).
48. See Gary Taubes, Apocalypse Not, 278 SCIENCE 1004, 1004 (1997) (reporting on some infectious disease
experts' criticism of the predictions that global warming will increase the prevalence of infectious diseases as the
Kyoto summit approached).
49. The connection between global public health policy and international environmental law was also seen
in the WHA's resolution supporting protection of marine environment in order to reduce risks to human health
from environmental degradation. See Protection of the Marine Environment, World Health Assembly Res.
WHA50.14 (May 12, 1997).
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5. Antimicrobial Resistance
Another infectious disease concern raised frequently in 1997 was the development of antimicrobial resistance in pathogens. While antimicrobial resistance was long a topic in EID literature,
worldwide publicity about the identification in Japan and the United States of strains of Staphylococcus aureus with decreased susceptibility to vancomycin created more public awareness of the
problem of antimicrobial resistance. The Institute of Medicine's Forum on Emerging Infections
explored antimicrobial resistance in its July 1997 meeting, including national and international
legal issues that antimicrobial resistance creates." The WHO held a meeting in October 1997
in Berlin on the use of antimicrobials in food-animals and the risks such use poses for human
health. In its report on this meeting, the WHO recommended that: (1)"governments institute
laws and regulations pertaining to anti-microbial licensure, prudent use and compliance"; and
(2) "[o]n the international level, agreements are needed to reduce the risk of transmitting
[anti-microbial] resistance between countries."" The WHO intends that reporting of antimicrobial resistance will form part of the syndrome notification obligations in the revised IHR."

II. AIDS
Developments in AIDS law reflected an uneasy balance of factors in 1997. The number of
people infected continued to expand, despite advances in drug therapies to treat those falling
ill. The expense of those therapies threatened to bankrupt national health care systems, even
as activists called for increased access. Governmental policies on AIDS reflected compassion
in some cases and ignorance in others. Court decisions advanced the rights of persons with
AIDS in areas of access to medical drugs, employment law, and travel.
A. HIV

ANTIBODY TESTING AND THE FURTHER SPREAD OF

AIDS

In a disturbing development, the Hungarian Parliament eliminated anonymous HIV testing."
The new law provides that when a person tests positive for HIV, "the person ... must provide
his personal identification data at the request of the provider of medical care. The person
...shall be informed of this prior to the screening examination." 4 Although the legislature
perhaps believed it could better track persons with HIV, the removal of anonymous testing
instead drives HIV underground and furthers its spread.
Infection rates for new cases of HIV continued to climb during 1997. UNAIDS estimated
that 5.8 million people were infected in 1997." In some places the rise in the number of new
50. INSTITUTE OF MED., U.S. NAT'L ACADEMY OF SCIENCES, ANTIMICROBIAL RESISTANCE, SURVEILLANCE, AND

(July 30-31, 1997). For legal issues, see David P. Fidler, Legal Issues Arising from the Development
of Antimicrobial Resistance in the Era of Emerging Infectious Diseases (unpublished manuscript, on file with
author).
RESPONSE

51. WORLD HEALTH ORG., THE MEDICAL IMPACT OFTHE USE OF ANTIMICROBIALS IN FOOD ANIMALS: REPORT
OF A WHO MEETING

(Berlin, Germany, Oct. 13-17, 1997).

52. Emerging and Otber Communicable DiseasesSurveillance andControl Strategic Plan 1996-2000, World Health
Organization, Division of Emerging and Other Communicable Diseases Surveillance and Control WHO/EMC/
96.1 (1996).
53.Rex Wockner, Hungary Halts Anonymous HIV Testing, CHI. OUrLINES, Dec. 17, 1997, at 1I.
54. The translation of the Hungarian law was supplied by The International Gay and Lesbian Human Rights
Commission, a San Francisco-based organization that monitors human rights violations against gay men, lesbians,
bisexuals, transgender people, and people with HIV and AIDS worldwide.
55. UNAIDS is the Joint United Nations Program on HIV/AIDS. It coordinates AIDS-related activities for
U.N. agencies including the United Nations Children's Fund, the United Nations Development Program, the
United Nations Population Fund, the United Nations Educational, Scientific, and Cultural Organization, the
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cases is simply staggering. In Kaliningrad, Russia, for example, where intravenous drugs and
commercial sex are reportedly widely available, the number of AIDS cases jumped from twentyeight in 1996 to more than 1,850 in 1997.6 China reported 7,253 cases of HIV infection,
but experts estimate that the true figure is 200,000 cases. 7 Experts at an AIDS Congress in
the Philippines estimated that the number of people in Asia affected by HIV, "already estimated
at 7 million, could double by the turn of the century." 8 The head of the AIDS Commission
in Uganda estimated that at least 400,000 Ugandans died from AIDS since 1984 and that 1.5
million of Uganda's 18 million people are infected with HIV."9
The number of cases is significant not only for epidemiological reasons, but because AIDS
60
increases poverty and decreases educational opportunities in the developing world. The World
Bank called on developing countries in 1997 to focus on AIDS prevention programs as part
of their development strategies. 6" Warning that the AIDS pandemic is about to explode in
China, India, and Eastern Europe, the World Bank urged developing nations to implement
controversial AIDS prevention programs," including needle exchanges and condom distribu-64
tion, 63 and a UNAIDS official urged private companies to join the battle against AIDS.
Preventive education remains the best hope for nations to control the further spread of AIDS.
B. AccEss

TO MEDICAL DRUGS

The newest approach to treating HIV combines a protease inhibitor with two or more
nucleoside analogues. 6 Drug combinations, sometimes called an "AIDS cocktail," can cost
$12,000 to 515,000 a year in the United States.66 These miracle drugs do not work for everyone,
as evidenced by the deaths of many having access to the drugs and following the protocol.
Countries providing access to the new medicines available to treat HIV found that their
AIDS death rates dropped significantly in 1997. Brazil, for example, saw its AIDS death rate
fall for the first time ever after distributing free AIDS treatment drugs.67 Of course, most nations
cannot afford to provide free drugs to those needing them. In the United States, a country

International Healtb Law, 31INT'L LAW, 645, 654
WHO, and the World Bank. See Maureen Bezuhly etal.,
(1996). Information about the organization's activities and current estimates of HIV infection rates are often
available on the UNAIDS website at < http://www.unaids.org>.
56. Michael Specter, At a Western Outpost of Russia, AIDS Spreads "Like a Forest Fire," N.Y. TIMES, Nov.
4, 1997, at Al.
57. ADVOCATE, Dec. 23, 1997, at 23.
58. ADVOCATE, Dec. 9, 1997, at 20.
59. Uganda, 96 CURRENT HisT. 400 (1997).
60. Lawrence K. Altman, AIDS Surge Is Forecastfor China, India and Eastern Europe, N.Y. T MEs, Nov. 4,
1997, at AI0.
61. Kai Wright, World Bank: Focus on Gays in AIDS Fight, WASH. BLADE, Nov. 28, 1997, at 12.
62. Despite the controversy surrounding some programs, certain nations show strong commitment to preventive education. Brazil, for example, announced in 1997 that its new education program will target children as
young as four years old with age-appropriate information. ADVOCATE, Feb. 4, 1997, at 21.
63. Altman, supra note 60, at AI0.
Feb. 28, 1997, at 10.
64. Christopher Jones, U.N. Official Urges Businesses to Figbt AIDS, WASH. BLADE,
65. AIDS 1997: A Look Back at the Year of Hope, ADVOCATE, Jan. 20, 1998, at 51,53. The combination
Id.
replication
of thevirus."
toa federal
taskforce,
"offers a 'high chance' of suppressing
therapy, according
66. Jerome Groopman, To Be Poorand Infected witb H..V, N.Y.TIMES, Nov.8,1997, atAl 5;Robert Pear,
Clinton To Seek More Money To Help Pay for AIDS Drugs, N.Y. TimEs, Dec. 30, 1997, at A14.
67. See, e.g., Laurie Goering, Latin Nations' Unique AIDS Plight Puzzles, Cm.TRIB.,Nov. 7, 1997, § 1, at
18.
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without a nationalized health system, federal spending on these drugs was estimated at $167
million in 1996, $285 million in 1997, and $385 million in 1998.68
As governments grapple with the expenses of these new drugs, they may find themselves
being sued by persons needing the drugs for their survival. One surprising and welcome decision
resulting from these cases came from the Supreme Court of Costa Rica. On September 23,
the court ordered the government health care agency, the Caja Costarricense de Seguro Social,
to provide AIDS medications to William Garcia, a man living with AIDS. 69 Garcia presented
prescriptions for AZT, 3TC, and Crixivan;' ° the Caja claimed it could not afford the drugs,
which could cost up to $900 per month in Costa Rica." Garcia's attorney offered affidavits
showing that the three pharmaceutical companies producing drugs in Costa Rica offer discounts
of up to fifty percent to the government if it buys the drugs in large quantities. 2 These large
discounts are possible in Costa Rica because the health care system is nationalized and "the
sole legal source of medication in the country.' 73
Although the court initially ruled only on behalf of Garcia, two days later the court also
ordered the Caja to provide AIDS medications to three other persons living with AIDS.' 4 It
is unclear how these rulings will affect an estimated 300 other persons in Costa Rica also
needing these expensive drugs." The ruling in favor of William Garcia came too late for him;
he died on October 12, 1997, less than a month after his court victory.' 6 On the Friday night
before his death, he told a friend he was very proud of his decision to go public with his
HIV-status and to sue the Costa Rican Government. He told his friend, "I have been very
77
brave."

Activists in other countries, such as Patrick Levy and Ricardo Schneider of the Israel AIDS
Task Force, followed the Costa Rican litigation closely and used it in arguing that Israel had
a duty to continue to supply protease inhibitors to persons living with HIV. Two of Israel's
national healthcare programs had stopped paying for the "cocktail" drug combinations after
the Israeli Ministry of Finance refused to pay for these treatments.'" The Ministry reversed
its decision, however, when it was presented with the Costa Rica example and other evidence
that protease-resistant strains of HIV might develop in Israel if the drugs were not supplied.
C.

EMPLOYMENT DISCRIMINATION

A landmark decision from the High Court of Bombay (Mumbai) extended the employment
rights of HIV-positive persons in India. The case involved a part-time employee recruited for
a full-time position, subject to a medical fitness examination. A medical expert certified that
the man was medically fit to perform his job, but that he was HIV-positive. The company
fired the man from his casual employment and instituted a new policy requiring HIV testing
68. Pear, supra note 66, at A10.
69. Kai Wright, Court Ruling Gives Man "AChance To Make It," WASH. BLADE, Oct. 10, 1997, at 12.
70. Rex Wockner, Costa Rican AIDS Pioneer Dies, CHI. OUTLINES, Oct. 29, 1997, at 11.
71. Wright, supra note 69.

Id.
73. Id.
74. Id. The case for these three persons and the case filed for William Garcia were filed by Marco Castillo,
attorney for a Costa Rican gay civil rights group, Triangulo Rosa. Id. See also Christopher Jones, Activists Open
72.

Doors of Third Community Center, WASH. BLADE, Mar. 21, 1997, at 10.
75. Id.
76. Kai Wright, Costa Rica: PlaintiffSuccumbs, WASH. BLADE, Oct. 17, 1997, at 14.

77. Wockner, supra note 70.
78. Rex Wockner, Israeli HealtbcarePrograms Witbbold AIDS Drugs, CHI.

OtrrLINES,

Oct. 29, 1997, at 11.
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as part of pre- and post-recruiting policy. The Lawyers' Collective, a public interest law group
in India represented by advocate Anand Grover, filed a petition to challenge the lawfulness
of the policy and to reinstate the employee with back pay. Justices Tipnis and Trivedi of the
Bombay High Court issued their landmark decision on April 3, 1997, finding it impermissible
for the company to condemn an HIV-positive person to "certain economic death.' 71 The
justices ordered the company to reinstate the employee and to pay his lost wages. Legal observers
noted that many HIV-positive persons suffering discrimination in India are afraid to litigate
their cases "for fear that their HIV status will become public knowledge." The victorious
employee obtained a landmark order, the first of its kind in India, allowing him to suppress
his identity and to litigate under a pseudonym to protect his privacy.
D.

DEGRADING TREATMENT OR PUNISHMENT

The European Convention on Human Rights prohibits "inhuman or degrading treatment
or punishment.""s The European Court of Human Rights, in a surprising decision, found that
the United Kingdom would violate this provision by deporting a cocaine smuggler with AIDS. s82'
The case involved a native of St. Kitts arrested in London for attempting to import cocaine.
He was convicted and sentenced to prison, where he was first diagnosed as having HIV."
Before he was released from prison, British immigration authorities began procedures to deport
the man to St. Kitts. His solicitors asked the Secretary of State to allow him to remain in the
United Kingdom "on compassionate grounds since his removal to St. Kitts would entail the loss
of the medical treatment he was currently receiving, thereby shortening his life expectancy."84 At
the time of the man's request, his CD4 cell count was below ten and he suffered from "recurrent
anemia, bacterial chest infections, malaise, skin rashes, weight loss and periods of extreme
fatigue." 5 The High Commission for the Eastern Caribbean States informed the man's doctor
that the medical facilities in St. Kitts could not provide the medical treatment he would require.8"
The Antigua and Barbados Red Cross, meanwhile, also confirmed that St. Kitts had "no health
87
care providing for drugs treatment of AIDS."
In reviewing the man's claim that deportation to St. Kitts would violate the European
Convention on Human Rights, the court took note of various AIDS resolutions, such as one
from the U.N. Commission on Human Rights that urged "all States to ensure that their laws,
policies and practices introduced in the context of AIDS respect human rights standards.' 88
The court also considered the health care the man would receive in the United Kingdom as
compared to the relative lack of care in St. Kitts.
79. MX v. ZY, 1997 A.I.R. 406 (Born. High Ct.).
80. Convention for the Protection of Human Rights and Fundamental Freedoms, entered into force Sept. 3,
1953, art. 3, 213 U.N.T.S. 222, as amendedby Protocols Nos. 3, 5, and 8, enteredintoforce Sept. 21, 1970, Dec.
20, 1971, and Jan. 1, 1990 respectively, reprinted in FRANE NEWMAN & DAVID WEISSBRODT,INTERNATIONAL
HUMAN RIGHTS: LAW, POLICY, ANDPROCESS-SELECTED INTERNATIONAL HUMAN RIGHTS INSTRUMENTS ANDBIBLIOGRAPHYFORRESEARCH
ON INTERNATIONAL HUMAN RIGHTS LAW 176, 177 (2d ed. 1996).

81. D. v. United Kingdom, 24 Eur. Ct. H.R. (ser. B) at 423 (1997).
82. Id. at 427.
83. Id. at 428. "The infection appears to have occurred some time before his arrival in the United Kingdom."
id.
84. Id.
85. Id. at 429.
86. Id. at 430.

87. Id.
88. Id. at 433. For more information on these and other international human rights instruments, see Mark
E. Wojcik, Global Aspects of AIDS, in DAVID W. WEBBER,AIDS ANDTHELAW (3d ed. 1997).
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The court concluded that returning the man to St. Kitts under these circumstances would
violate his human rights, despite his illegal status in Great Britain:
It is not disputed that his removal will hasten his death. There is a serious danger that the conditions
of adversity which await him in St. Kitts will further reduce his already limited life expectancy
and subject him to acute mental and physical suffering. Any medical treatment which he might
hope to receive there could not contend with the infections which he may possibly contract on
account of his lack of shelter and of a proper diet as well as exposure to the health and sanitation
problems which beset the population of St. Kitts. While he may have a cousin in St. Kitts no
evidence has been adduced to show whether this person would be willing to or capable of attending
to the needs of a terminally ill man. There is no evidence of any other form of moral or social
support. Nor has it been shown whether the applicant would be guaranteed a bed in either of
the hospitals on the island which, according to the government, care for AIDS patients. 9
While cautioning other illegal aliens that they should not expect similar rulings, the court
ordered Great Britain to stop deportation proceedings and to provide necessary medical care
to this man who entered the country as an attempted cocaine trafficker.9" To deport him would

be "inhumane treatment" in violation of the European Convention on Human Rights. 9

E.

MEDIA LAW

One AIDS-related development arose in an advertising campaign by Benetton, a company
famous for its controversial advertisements. The company developed a series of posters showing
parts of the human body tattooed with the words "HIV Positive." 92 A French court found
that the posters were offensive to persons livingwith HIV and abused the freedom of expression."'
The company was ordered to stop the campaign and to pay damages."4
III. International Tobacco Control
The global tobacco pandemic presents an extraordinary public health challenge." Currently,
tobacco is responsible for 3.5 million deaths per year, with two-thirds of these deaths occurring

in industrialized nations.96 Cigarette smoking, the predominant form of tobacco use, is one of
the largest causes of preventable death worldwide and is the leading cause of premature death
in developed countries."7 Although the vast majority of those killed thus far by the tobacco
epidemic were in industrialized nations, with cigarette sales in industrialized states stagnating,
the transnational tobacco industry successfully focused in the last several decades on penetrating

89.
90.
91.
92.
93.
94.
95.

D. v. United Kingdom, 24 Eur. Ct. H.R. at 448.
Id.
at 448-49.
Id.
at 448.
Benetton Group S.P.A. v. Association AIDES Fed'n Nationale, 3 Euro. Current L. 102 (1997).
Id.
Id.
For an extensive discussion of the global tobacco pandemic and the role of national legislation in achieving

worldwide tobacco control, see generally RUTH ROEMER,LEGISLATIVE AcroN TO COMBAT

THE

WORLD TOBACCO

EPIDEMIC (2d ed. 1993). See also Allyn L. Taylor, An International
Regulatory
Strategy
forGlobal
Tobacco
Control,
21 YALE J. INT'L L. 257 (1996).
96. RICHARD PETO Er. AL., Global Tobacco Mortality, Paper Presented at the Tenth World Conference on
Tobacco or Health, Beijing, China (1997) (on file with author).
97. WORLD HEALTH ORGANIZATION, FAcTs AND FIGURES:WoRLD No TOBACCO DAY (1994). Smoking will

be responsible for an estimated 60 million premature deaths in developed states between 1950 and 2000, 37.8
million of the victims being between the ages of 35 and 69. See generally, RICHARD
PEro ET. AL., MORTALITY
FROMSMOKINGIN DEVELOPED
CoTrRIES 1950-2000 (1994).

SUMMER 1998

550

THE INTERNATIONAL LAWYER

and expanding new markets in Africa, Asia, Latin America, Eastern Europe, and the former
98
states of the Soviet Union, where tobacco regulation is weak or non-existent. The WHO
predicts that if current trends persist over the next thirty years, seven million inhabitants of
developing nations will die annually from smoking related diseases, accounting for seventy
99
percent of tobacco-related deaths worldwide. Hence, within the next thirty years, smoking
will not only be the leading cause of premature mortality in developed states, but also the
leading cause of premature death globally.
A. WORLD HEALTH ORGANIZATION

In order to counter the successful efforts of the transnational tobacco industry to penetrate
markets worldwide, the WHO launched an international regulatory strategy for global tobacco
control in May 1996. As recommended in the official background report on multilateral regulatory alternatives for tobacco control prepared for the WHO's Executive Board and the WHA, 0
the WHA adopted a resolution calling upon the Director-General of the WHO to: (1) initiate
the development of a framework convention on tobacco control in accordance with article 19
of the WHO Constitution; and (2) to include as part of this framework convention a strategy
to encourage member nations to move progressively toward the adoption of comprehensive
tobacco control polices, and also to deal with aspects of tobacco control transcending national
boundaries.'
In 1997 the WHO endeavored to build support for the development of a framework convention on tobacco, holding its first consultative meeting on member states to the proposed convention in June 1997.' In addition, the WHO's international regulatory strategy for tobacco
control was officially endorsed by a variety of groups and organizations in 1997, including the
0
American Public Health Association' ' and the 10th World Conference on Tobacco or
Health."°4 Further, the United Nation's Conference on Trade and Development, the U.N. focal
point on tobacco, established and strengthened contacts with governments, nongovernmental
organizations, and over thirty U.N. organizations, particularly in5 the area of information and
exchange of communications among concerned organizations.

98. Judith Mackay, Lessons from the Conference: The Next 25 Years, Paper Presented at the Tenth World
Conference on Tobacco or Health, Beijing, China (1997) (on file with author).

99. PETO ET AL., supra note 96, at 2.
100. Allyn L. Taylor & Ruth Roemer, InternationalStrategy for Global Tobacco Control, WHO Doc. WHO/
PSA/96.6 (1996). For the background proposal for the global regulatory approach to tobacco control, see Allyn
L. Taylor, International Legislation To Combat the Tobacco Pandemic, Paper Presented at the Ninth World
Conference on Tobacco or Health, Paris, France (1994) (on file with author).
101. InternationalFrameworkConventionfor Tobacco Control, WHA RES. 49.17, WHO Doc. A49/VRI6 (1996).

102. Allyn L. Taylor, International Regulatory Approaches to Promote Global Public Health: The Operation
of an International Framework Convention-Protocol Approach for Global Tobacco Control, Paper Presented at
the World Health Organization Consultative Meeting on International Tobacco Control, Halifax, Nova Scotia
(1997); Eric LeGresley, Options for the Preparation of an International Framework Convention and Related

Protocols for Tobacco Control: Public Health and International Law Considerations, Paper Presented at the
World Health Organization Consultative Meetingon International Tobacco Control, Halifax, Nova Scotia (1997).

103. An InternationalTobacco Control Policy, Resolution Adopted by the Governing Council of the American
Public Health Association, Indianapolis, Indiana (Nov. 12, 1997).
104. Resolutions of tbe Tentb World Conference on Tobacco or Healtb, art. 11,Beijing, China (Aug. 24-28, 1997).
105. See Coordination Questions: MultisectoralCollaborationon Tobacco or Healtb: ProgressMade in the Implementation of Multisectoral Collaborationon Tobacco or Healtb, Report ofthe Secretary General, Economic and Social Council,
ECOSOC Doc. E/1997/62 (1997).
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On June 27, 1997, a pact was reached between state attorney generals and the American
tobacco industry in which the tobacco companies agreed to pay $ 368.5 billion over the next
twenty-five years to compensate states for the costs of treating tobacco-related illness, to finance
nationwide anti-smoking programs, and to underwrite health care for millions of uninsured
children." 6 The proposed settlement, which must be approved by the President and by Congress,
also contains diverse measures designed to restrict advertising and marketing of tobacco to
children. Numerous public health authorities, including a Congressional advisory panel headed
by former Surgeon General, C. Everett Koop and former FDA Commissioner, David A. Kessler,
condemned the proposed settlement, °7 the fate of which is highly uncertain. 0 8 In addition,
a number of public health experts 0 9 and members of Congress"o criticized the proposed settlement for failing to address the transnational activities of American tobacco conglomerates.
In response to widespread criticism that U.S. trade policy aggressively promotes American
tobacco abroad, at the end of 1997 the U.S. Congress passed a law, introduced by Congressman
Lloyd Doggett, that prohibits U.S. Government officials from: (1) promoting tobacco or tobacco
products overseas, or (2) opposing tobacco-related laws in another country, provided such laws
are applied equally to foreign and domestic products.I'
C.

EUROPEAN UNION

In 1997 European health ministers agreed on a sweeping initiative to ban most forms of
tobacco advertising by 2006. "2The European Parliament is expected to approve the agreement
next year."' The comprehensive advertising ban prohibits most forms of direct and indirect
tobacco advertising, sponsorship, and promotion in the name of tobacco products or producers.
Most forms of advertising will be banned three years after the Parliament approves the legislation.
However, to accommodate some member states, the proposed Directive allows delayed implementation of the tobacco sponsorship ban for major
worldwide sporting events, such as Formula
4
One and the world snooker championships."

106. US. Tobacco Settlement Proposal, <http://stic.new.edu/settlement/6-20-settle.htm>.
107. ADVISORY COMM. ON TOBACCOPOLICY AND PUBLICHEALTH, FINAL REPORT(Co-Chairs C. Everett Koop
& David A. Kessler) (July 1997); BRION J. Fox, ET. AL..,ANALYSIS OF THE PROPOSED
RESOLUTION OF THE UNITED

STATES
TOBACCO LITIGATION (University of Cal. Inst. for Health Policy Studies) (1997).
108. See, e.g., Jeffrey Taylor, Clinton Presses Tougher Deal on Tobacco, WALL ST. J., Sept. 18, 1997, at A3;
John M. Broder, Tobacco Accord Faces Delay in Congress, N.Y. TMES, Sept. 4, 1997, at Al.
109. See, e.g., Greg Connolly, The $ 360 Billion Global Settlement: Will the Women and Children of Asia
Pay the Bill?, Paper Presented at the Tenth World Conference on Tobacco or Health, Beijing, China (1997);
Eric LeGresley, Slaying the Leviathan: Stray Bullets and Other Foreign Consequences (unpublished manuscript,
on file with author); Allyn Taylor, International Action for Tobacco Control, Paper Presented at the 125th
Annual Meeting of the American Public Health Association, Indianapolis, Indiana (1997); BRION J. Fox ETAL.,
INTERNATIONAL ISSUES
RELATIVE TO THE TOBACCO DEAL (University of Cal. Inst. for Health Policy Studies) (1997).

110. See, e.g., Albert R. Hunt, Waitingfor Clinton To Lead, WALL ST. J. INTERACTIVE EDITION, Sept. 18, 1997.
111. Departments of Commerce, Justice and State, the Judiciary, and Related Agencies Appropriations Act
of 1997, Pub. L. No. 105-119, I11 Stat. 2440 (1997).
112. See, e.g., Edmund L. Andrews, EuropeanOfficials Agree To Ban on Most Tobacco Ads by 2006, N.Y. TIMES,
Dec. 5, 1997, at Al. The principle of the proposed Directive is to ban all forms of tobacco advertising, and
promotion, apart from television advertising, which was banned by a previous Council Directive.
113. Id
114. Id.
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IV. Judicial Decisions by International and Foreign Bodies
A.

DECISIONS FROM THE EUROPEAN COURT OF JUSTICE

(ECJ

OR COURT)...

16

1. Harry Franzin' -Swedisb Alcohol Monopoly Ruled Legal
On October 23, 1997, the ECJ ruled that Sweden's state monopoly on the sale of alcohol
does not violate article 37 of the EC Treaty because, inter alia, the Alkohollag, the Swedish
7
Law on Alcohol (the Law), is justified on public health grounds." However, the court held
of the EC Treaty because:
30
and
36
articles
violates
licensing
system
alcohol
that Sweden's
(1) it discriminates against imported products,' and (2) less restrictive alternatives are available
to ensure a public health objective." 9
The ECJ was asked by a tribunal in the southern Swedish town of Landskrona, where
wholesaler Harry Franz~n was being prosecuted for selling wine without a license, to rule
whether the alcohol monopoly known as Systembolaget Aktiebolag (Systembolaget), a company
wholly owned by the Swedish state, contravened the EC Treaty. The Law subjects individuals
intentionally or inadvertently selling or producing alcoholic beverages without a license to
criminal liability.' 20 Although Franzen had no license to sell alcohol, he argued he could not
be convicted under Swedish law because the result would breach EC Treaty provisions on
state monopolies and the free movement of goods.' 2 '
The court acknowledged that the Law, effective January 1, 1995, properly regulates both
production and trade in alcoholic beverages.' 2 The court further recognized that the Law's
objective is aimed particularly at limiting the consumption of beverages having a high alcoholic
content in order to reduce the harmful effects their consumption has on human health.' 2'
The Law provides for two types of licenses: production licenses and wholesale licenses.' 24

115. The European Court of Justice (ECJ) is the main judicial institution of the European Community and
applies Community law to the cases before it. The ECJ is comprised of fifteen Judges and nine Advocates General.
The role of the Advocate General is to present a reasoned and independent opinion of the issues of law in the
case.
116. Case 189/95, Franzcn, CEC (CCH) (1997) [hereinafter Franzen].
117. Id.
39, 52. Article 37 of the EC Treaty provides in relevant part: "Member States shall progressively
adjust any State monopolies of a commercial character so as to ensure ...no discrimination regarding the conditions
under which goods are procured and marketed exists between nationals of Member States." Treaty Establishing
the European Economic Community, Mar. 25, 1957, 298 U.N.T.S. 11 [hereinafter EC Treaty].
71. Article 30 of the EC Treaty provides: "Quantitative restrictions on
118. Franzen, supra note 116,

imports and all measures having equivalent effect shall, without prejudice to the following provisions, be prohibited
between Member States." EC Treaty, supra note 117, art. 30. Article 36 of the EC Treaty provides in relevant
part:
The provisions of Arts. 30 to 34 shall not preclude prohibitions or restrictions on imports, exports
or goods in transit justified on grounds of public morality, public policy or public security; the
protection of health and life of humans .... Such prohibitions or restrictions shall not, however,
constitute a means of arbitrary discrimination or a disguised restriction on trade between Member
States.
Id. art. 36.
119. Franz~n, supra note 116, 4 75, 76.
120. Id. 19.
121. Id.

32.

122. Id. 5,6, & 33.
123. Id. 3.
5, 6, & 70. Under the Law, licenses are issued for a substantial fee by the Alkoholinspektion
124. Id.
(Alcohol Inspectorate). Submission of a license application issubject to a fixed charge of SKR 25,000. Additionally,
the State requires an annual fee of between SKR 10,000 and 323,750, depending on the type of beverages and
quantities produced or marketed. Id.
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Importation of all wine, strong beer, and spirit drink into Sweden is subject to the possession
of a production or wholesale license.' Also, pursuant to the Law, Systembolaget has the
exclusive right to sell all wine, strong beer, and spirits in Sweden.' The court observed that
the purpose of article 37 of the EC Treaty is to permit Member States to maintain certain
commercial monopolies in order to pursue public interest aims with minimal impact on the
free movement of goods.2 7 The court additionally noted that "in aiming to protect public
health against the harm caused by alcohol, a domestic monopoly on the retail of alcoholic
beverages, such as that conferred on Systembolaget, pursues a public interest aim,"' 2 8 the court
found that because "the criteria and selection methods used by Systembolaget do not appear
to be either discriminatory or apt to put imported products at a disadvantage ... . [Ilt appears
that a retail monopoly such as that in question in the main proceedings meets the conditions
for being compatible with Article 37 of the Treaty .... ",'"
Notwithstanding the foregoing, the court rejected the Swedish Government's contention
that its alcohol licensing scheme is reasonably tailored to achieve public health objectives. The
court stated that:
The licensing system constitutes an obstacle to the importation of alcoholic beverages from other

Member States [in] that it imposes additional costs on such beverages, such as intermediary costs,
payment of charges and fees for the grant of a license, and costs arising from the obligation to
maintain storage capacity in Sweden."'
In this regard, the court determined as follows:
Although the protection of human health against the harmful effects of alcohol on which the
Swedish government relies, is indisputably one of the grounds which may justify derogation from
Article 30 of the Treaty, the Swedish Government has not established the licensing system set
up by the Law on Alcohol, in particular as regards the condition relating to storage capacity and
the high fees and charges which license-holders are required to pay, was proportionate to the

public health aim pursued or that this aim could not have been attained by measures less restrictive
of intra-Community trade." 2
The court thus concluded that the licensing system established by the Law was contrary to
article 30 of the EC Treaty.' Interestingly, the court's decision to uphold Sweden's alcohol
monopoly was contrary to the advisory opinion of the court's Advocate General,"' who
proposed that the Swedish monopoly system was prohibited by articles 30 and 37 because
Systembolaget controlled which products would be imported into Sweden from other Member
States. However, the ECJ agreed with that portion of the Advocate General's opinion that
Sweden's licensing system could not be justified on grounds of protection of health and life
of humans, as provided in article 36, because such protection could be ensured by measures
less restrictive of the free movement of goods.

125. Id.
126. Id.1

15,16.

127. Id.

39.

128. Id.

41.

129.
130.
131.
132.
133.
134.

Id. 52.
Id. 66.
Id. 71.
Id. 76.
Id. 75.
Advocate General M.B. Elmer delivered his opinion at the sitting of the full court on March 4, 1997.
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2. Maria Antonella Garofalo and Otbers v. Ministero della Sanita'"-Doctors' Rigbts to Practice
General Medicine Recognized
On October 16, 1997, the ECJ ruled that an E.U. member state must recognize the right
of a doctor to practice medicine in its territory-even if that doctor does not possess a general
medical practitioner's diploma-provided that the doctor acquired the right to practice general
medicine under the Member State's national security scheme prior to January 1, 1995.,36 The
ruling was an interpretation of Council Directive 93/16/EEC,"'3 April 15, 1993, on the mutual
recognition of diplomas, certificates, and other evidence of formal medical qualification. Council
Directive 93/16/EEC provides in relevant part:
1. From 1 January 1995, and subject to the acquired rights it has recognized, each Member
State shall make the exercise of general medical practice under its national social security scheme
conditional on possession of a diploma, certificate or other evidence of formal qualification ...
2. Each Member State shall specify the acquired rights that it recognizes. However, it shall recognize
the right to exercise the activities of general medical practitioners under its national social security
scheme without the diploma, certificate or other evidence of formal qualification ... as having
been acquired by all those doctors who on 31 December 1994 possess such a right ... and who
are established on its territory on that date ...
This case originated as a petition by eleven doctors to the Italian Ministry of Health."3 The
petitioners sought to exclude from the list of practitioners under contract with the Palermo
Local Health Unit the names of doctors not having diplomas in general practice. Italian law
implementing Council Directive 93/16/EEC1 9 recognized the rights of all doctors authorized
to practice medicine before January 1, 1995, as general practitioners in the public health
system." The petitioners claimed Council Directive 93 / 16/EEC requires doctors to have entered
into a service relationship with a member state's national health system prior to January 1,
1995, in order to practice medicine in that state without a general medical practitioner's
diploma.141
The Italian Ministry of Health sought the opinion of the Italian Council of State (Consiglio
di Stato).142 The Council of State, in turn, referred two questions to the court for review: (1)
whether Council Directive 93/16/EEC' 4 ' requires a doctor to have entered into an actual service
relationship with a Member State's national health system prior to January 1, 1995, in order
to practice medicine in that state without a general medical practitioner's diploma; and (2) if

135. Case 69/96-79/96, Garofalo v. Ministero della Saniti, CEC (CCH) (1997) [hereinafter Garofalo].
136. A preliminary issue was raised as to whether the Italian Council of State was a "court or tribunal" for
purposes of petitioning the ECJ. The court recognized the Council of State as such, noting its impartial, adversarial,
and independent nature.
137. Council Directive 93/16/EEC of 5 April 1993 To Facilitate the Free Movement of Doctors and the
Mutual Recognition of Their Diplomas, Certificates and Other Evidence of Formal Qualifications, 1993 OJ. (L
165) [hereinafter Council Directive 93/16/EEC].
138. The Italian Ministry of Health plans, coordinates, and implements actions for the prevention and control
of communicable diseases. It is also the WHO counterpart for the Expanded Programme on Immunization and
for the surveillance of infectious diseases and Tuberculosis in Italy.
139. Council Directives are addressed to Member States and are binding as to the result, but the Members
may choose to modify the form and method of implementing the Directives to adapt to individual national legal
systems.
140. Garofalo, supra note 135,
11-13.
141. Id. 13.
142. Id. 14.
143. Council Directive 93/16/EEC, supra note 137.
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so, whether a Member State has the discretion to extend the right to practice medicine to
doctors qualified to practice as of January 1, 1995, but who did not enter into a service
relationship with the Member State as of that date.'
The ECJ ruled as to the first question that each Member State has discretion to determine
the acquired rights of doctors subject to only one condition, namely that each Member State
must recognize the acquired rights of those doctors not holding a general medical practitioner's
diploma but who, before January 1, 1995, were recognized in that Member State as having
a diploma, certificate, or other evidence of formal qualification issued to them in another
Member State and who, also before that date, obtained the right to exercise the activities of
general medical practitioner under the national social security scheme.' 45 As to the second
question, the court determined that the fact that doctors "have not actually entered into a
service relationship with the national social security scheme does not prevent doctors who have
acquired the right to enter into such a relationship from subsequently establishing one." 46
3. Merck & Co., Inc. (Merck) and Otbers v. Primecrown Ltd (Primecrown)and Otbers and
Beecham Group plc v. Europbarm of Wortbing Ltd. (Europbarm) Ruling-Pbarmaceutical
Companies May Not Prevent ParallelImportation
On December 5, 1996, the court ruled that parallel importation of patented pharmaceutical
products is permissible among Member States. 48 Merck claimed Primecrown infringed its
patents for several drugs marketed in the United Kingdom by carrying out parallel imports of
the drugs into the United Kingdom from Spain and Portugal, where patents for the drugs are
4
not recognized, and where generic versions of the drug are available at substantially less cost.1 1
°
Beecham made a similar complaint against Europharm.s
The court held that articles 30 and 36 of the EC Treaty prohibited holders of a patent for
pharmaceutical products from preventing third parties from importing those products from
another Member State when the patent holder put the product on the market in that State
after its accession to the Community, but before the product could be protected by a patent
in that State."' The court reasoned that if a patentee is permitted "[to] prohibit the importation
of protected products marketed in another Member State by him or with his consent, he would
be able to partition national markets and thereby restrict trade between Member States.""'
The ECJ recognized an exception to the foregoing ruling that:
where a patentee is legally bound under either national law or Community law to market his
products in a Member State, he cannot be deemed ... to have given his consent to the marketing
of the products concerned ....

[and] is therefore entitled to oppose importation and marketing

of those products in the State where they are protected. "'

144. Id. IS.
145. Garofalo, supra note 135, 1 17.
146. Id. 1 19.
147. Cases 267/95-268/95, Merck & Co., Inc. v. Primecrown Ltd.; Beecham Group PLC v. Europharm of
Worthing Ltd., CEC (CCH) (1997).
148. Id.
36, 37.
149. Id. 1 2, 3, & 5.
150. Id. 14.
151. Id. 11 26, 36, & 37.
152. Id. 36.
153. Id. 50.
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However, the court did not recognize such an exception when patentees might be ethically
obligated to market their products." 4
Notwithstanding the court's decision in Merck, the debate between pharmaceutical manufacturers and importers continues. The manufacturers argue parallel importation threatens the
ability to conduct continuing medical research necessary to develop new drugs. The importers
assert that the availability of a cheaper product benefits poor persons and enables a larger
segment of the public to enjoy the benefits of the latest pharmaceutical technology.
Health officials and public health authorities took issue with the court's ruling in Merck,
stating that the court's decision overlooked the importance of ethical obligations to ensure patient
access to medicines in Member States with lower standards of patent protection. Litigation over
this topic is destined to erupt in the near future.
B.

ADVISORY OPINIONS OF THE ADVOCATES GENERAL OF THE

ECJ

1. The National Farmers' Union and Others v. The Ministry of Agriculture, Fisheries and Food,
the Commissionersfor Customs and Excise' -Opinion Restrictions on Beef Exportationfrom
the United Kingdom
A long-awaited decision is expected in 1998 in connection with the U.K.'s application for
the annulment of Decision 96/239156 (the Decision), which established a worldwide ban on
beef exportation from the United Kingdom for human consumption. However, if the recent
advisory opinion of the ECJ's Advocate General on September 30, 1997, is any indication,
the worldwide ban on British beef is likely to remain in effect.
On September 30, 1997, Advocate General G. Tesauro delivered an opinion stating that the
Decision, prohibiting the United Kingdom from exporting live cattle, meat, and other products
obtained from bovine animals to other Member States or to non-Member countries, isvalid. The
opinion was rendered in connection with two cases currently pending before the court concerning
the containment of bovine spongiform encephalopathy (BSE) or "mad cow disease."
The first case involves a reference from a preliminary ruling from the U.K.'s High Court
ofJustice, Queen's Bench Division, as a result of proceedings commenced by the British National
Farmers' Union (the Union). The Union challenged the measure adopted by British authorities
in response to the Directive on three grounds: (1) the Commission was without authority to
issue the Decision because its primary purpose is to reassure consumers and not to combat a
public health hazard; (2)the Commission lacked power to ban exports to non-Member countries;
and (3) less restrictive means are available to accomplish the desired goal.

154. Id. 53.
155. Cases 157196, 180/96, The Nat'l Farmers' Union v. The Ministry of Agric., Fisheries and Food, the
Comm'rs for Customs and Excise, Court of Justice Press Release No. 57/97 (Sept. 30, 1997) (Advocate General
G. Tesauro).
156. Commission Decision 961239/EC of 27 March 1996 on Emergency Measures To Protect Against Bovine
Spongiform Encephalopathy, 1996 O.J. (L 078). Article I of the decision prohibits the United Kingdom from
exporting:
* live bovine animals, their semen, and embryos,
* meat of bovine animals slaughtered in the United Kingdom,
* products obtained from bovine animals slaughtered in the United Kingdom which are liable
to enter the animal feed or human food chain, and materials destined for use in medicinal
products, cosmetics, or pharmaceutical products; and
* mammalian derived meat and bone-meal.
The decision was modified by Commission Decision 96/362 of June 11, 1996, adding several more restrictions
to article 1.
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The second case is a direct action by the United Kingdom against the Commission seeking
an annulment of the Decision on the same grounds as the Union, and on the additional ground
that the Decision unfairly discriminates against the United Kingdom. On July 12, 1996, the
ECJ denied the U.K.'s application for interim suspension of the Decision.
The Advocate General opined that Council Directives 90/42 5...and 89/66215' (on veterinary

checks and trade in live animals) confer broad latitude upon the Commission to adopt measures
necessary to combat serious hazards to the health of both humans and animals. According to
the Advocate General, the existence of health hazards justifies appropriate restrictions on the
free movement of goods, including exportation to non-Member countries. Restrictions with
respect to non-Member countries are necessary to ensure the ban is not thwarted by transit
through non-Member countries.
The Advocate General's opinion, though influential, is not binding on the ECJ. The ECJ
is expected to hand down a formal judgment in 1998. The Advocate General's opinion followed
the release of scientific evidence that comes close to providing a link between BSE and the
new variant of Creutzfeldt-Jakob disease in humans.
2. Lisa Jacqueline Grant v. Soutb-West Trains Ltd 59-Equal Benefits for Same Sex Couples
On September 30, 1997, Advocate General M. B. Elmer recommended the court hold that
an employer's denial of travel concessions to the same sex partner of an employee breached
European law guaranteeing equal pay. In this case, the employee commenced a proceeding in
an industrial tribunal after being refused concessions that were made available to her male
predecessor for his unmarried female partner.
On February 17, 1998, the ECJ rejected the Advocate General's recommendation and held
that:
an employer isnot required by Community law to treat the situation of a person who has astable
relationship with a partner of the same sex as equivalent to that of a person who is married to
or has a stable relationship outside marriage with a partner of the opposite sex. 0
The ECJ further held that such treatment does not constitute discrimination prohibited by
article 119 of the EC Treaty.

157. Council Directive 90/42 5/EEC of 26June 1990 Concerning Veterinary and Zootechnical Checks Applicable in Intra-Community Trade in Certain Live Animals and Products with a View to the Completion of the
Internal Market, 1990 O.J. (L 224).

158. Council Directive 891622/EEC of 11December 1989 Concerning Veterinary Checks in Intra-Community
Trade with a View to the Completion of the Internal Market, 1989 OJ. (L 395).
159. Grant v. South-West Trains Ltd., Case 249/96, Court of Justice Press Release No. 58/97 (Sept. 30,
1997) (Advocate General M. B. Elmer).
160. Id. 35.
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